PCSK9 Antisense Oligonucleotide Conjugates for Liver-Targeted LDL Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Antisense nucleic acids targeting PCSK9 face issues with higher-order structures, pharmacokinetics, and tissue specificity, leading to potential toxicity and reduced efficacy, as seen in the case of SPC5001, which was terminated due to kidney damage in clinical trials.

Innovation Solution

Designing antisense nucleic acids with high biostability and binding affinity for the PCSK9 gene using the Ca2+ enrichment of medium (CEM) method, and modifying them with specific sugar residues and asialoglycoprotein receptor-binding molecules to enhance liver targeting and reduce toxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antisense nucleic acids are designed to inhibit PCSK9 expression, then LDL cholesterol levels are reduced, but higher-order structures and complexes form affecting pharmacokinetics and efficacy

Engineering Contradiction:

ImprovePCSK9 expression inhibitionVSAvoidhigher-order structures and complexes

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent modifies the chemical structure of antisense nucleic acids by incorporating locked nucleoside analogs with bridging structures between 4' and 2' positions, changing the physical-chemical parameters to prevent higher-order structure formation while maintaining PCSK9 inhibition activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates conjugates combining antisense nucleic acids with asialoglycoprotein receptor-binding molecules (such as GalNAc), forming composite structures that improve pharmacokinetics and prevent unwanted complex formation while maintaining target inhibition

Inventive Principle:

Principle #40Composite materials

2Object-affected harmful factors

If antisense nucleic acids are modified with asialoglycoprotein receptor-binding molecules to enhance liver targeting, then tissue specificity is improved, but device complexity increases

Engineering Contradiction:

Improvetissue specificityVSAvoidconjugate structure

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent divides the functional components into separate segments: the antisense nucleic acid portion for PCSK9 inhibition and the asialoglycoprotein receptor-binding molecule portion for liver targeting, allowing independent optimization of each function while reducing overall complexity

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The asialoglycoprotein receptor-binding molecules serve multiple functions: they provide liver targeting specificity, improve pharmacokinetics, and prevent off-target effects, making a single modification highly versatile

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Quantity of substance

If standard therapy using statins or ezetimibe is used to control LDL-C, then cholesterol synthesis is inhibited, but PCSK9 expression is upregulated and atherosclerosis progression cannot be prevented

Engineering Contradiction:

ImproveLDL-C levelVSAvoidatherosclerosis progression prevention

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

Instead of using statins that inhibit cholesterol synthesis and inadvertently upregulate PCSK9, the patent directly targets and inhibits PCSK9 expression through antisense nucleic acids, reversing the problematic feedback loop and achieving sustained LDL-C reduction without atherosclerosis progression

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The resulting oligonucleotide conjugates effectively inhibit PCSK9 expression in vivo with low toxicity, offering a therapeutic option for high LDL cholesterol levels and associated diseases.

Implementation Method 1

the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4′ and 2′ positions

Methodology Applied

Scientific EffectConformational restriction:

Implementation Method 2

two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 3

the oligonucleotide is complementary to a human PCSK9 gene, and has inhibitory activity on expression of the human PCSK9 gene

Methodology Applied

Scientific EffectComplementary base pairing:

Data Source

PatentUS12544449B2Antisense nucleic acid targeting PCSK9

Publication Date: 2026.02.10 NAT CEREBRAL & CARDIOVASCULAR CENT

AI summary

Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4′ and 2′ positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.